financetom
Business
financetom
/
Business
/
Cannabis Ancillary Company Urban-Gro's Stock Plunges On Reporting Q4 & 2023 Results, Here's Why
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cannabis Ancillary Company Urban-Gro's Stock Plunges On Reporting Q4 & 2023 Results, Here's Why
Mar 28, 2024 12:25 PM

When design-build provider to the cannabis industry Urban-Gro ( UGRO ) announced its financial results Wednesday for the full year and 4Q 2024, the company's stock price plunged to $1.4 - a 23.42% decrease in just 24 hours

The report indicates a net loss of $18.7 million, an 18,2 percent increase as compared to $15.3 million in 2023. Adjusted EBITDA was also increasingly negative at 9.7 as compared to $3.9 in 2023. Revenue YoY increased $6.7% from $7.1 million to $67 million.

The company attributes the hurdles to shifts in the market and a backlog of $110 million.

FY 2023 Financial Highlights

Revenue of $71.5 million, a 4,5 million increase compared to 2023

Net Loss of $18.7 million

Adjusted EBITDA increased from negative 3.9 to negative 9.7 million

Q4 2023 Financial Highlights

Revenue decreased YoY from $15.0 million in 2024 to $17.3 million in 2023.

Gross profit was $1.7 million, also a decrease YoY.

Net loss was $4.7 million, or $(0.40) per share.

Adjusted EBITDA was negative $3.0 million as compared to negative $1.7 million in 2023

Management Confident In Future Positive Changes

Chairman and CEO Bradley Nattrass regarded 2023 as a "transitional year" in which the company deployed a diversification strategy, following shifts in the market. He said an increase of $26.4 million in revenue during 2023 came from construction but was offset by a significant decrease of $20.7 million in equipment systems revenue.

While this shift reflects a continuation of significantly reduced demand in the CEA sector, critical comments about the ongoing state-level regulatory delays in the license-awarding process were made, as well as the lack of movement on passing key legislation impacting the industry at a federal level.

"We continue to see strong momentum across multiple sectors and with the increased productivity in our services delivery to start the year, we expect to realize margin improvement as well," Natrass said. "Our guidance implies a strong year of organic growth based on the latest estimates of project timing and the impact of our streamlined operating structure."

Management added that many projects were delayed and pushed into fiscal year 2024 and is confident in the future profitability. The company expects the backlog entering 2024 will translate to a revenue increase of more than $84.0 million in 2024, representing growth of at least 17.4% and Positive Adjusted EBITDA for the current year.

Learn more about companies' strategies in a shifting market at the upcoming Benzinga Cannabis Capital Conference in Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars - this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com - Prices will increase very soon!

 

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ibotta Insider Sold Shares Worth $530,770, According to a Recent SEC Filing
Ibotta Insider Sold Shares Worth $530,770, According to a Recent SEC Filing
Sep 13, 2024
04:57 PM EDT, 09/13/2024 (MT Newswires) -- Thomas D Lehrman, Director, on September 11, 2024, sold 10,354 shares in Ibotta ( IBTA ) for $530,770. Following the Form 4 filing with the SEC, Lehrman has control over a total of 690,703 shares of the company, with 219,947 shares held directly and 470,756 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1538379/000162828024040365/xslF345X05/wk-form4_1726260698.xml Price: 56.51, Change:...
FDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System
FDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System
Sep 13, 2024
03:25 PM EDT, 09/13/2024 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said Friday the US Food and Drug Administration approved Roche's subcutaneous treatment for multiple sclerosis using Halozyme's drug delivery technology for a faster, twice-a-year 10-minute administration. The FDA's approval of Ocrevus Zunovo is based on phase 3 trial data, which showed non-inferior levels of the medicine in the...
CGI Completes Acquisition of Aeyon to Boost Services to the U.S. Government
CGI Completes Acquisition of Aeyon to Boost Services to the U.S. Government
Sep 13, 2024
04:33 PM EDT, 09/13/2024 (MT Newswires) -- CGI Inc. (GIB-A.TO) on Friday said CGI Federal, its U.S. unit completed the acquisition of Aeyon, a company involved in digital transformation and Artificial Intelligence technologies for the U.S. Federal government. The company first announced the acquisition on July 31. The price it paid for Aeyon was not disclosed. The acquisition complements and...
Newpark Resources Sells Fluids Systems Segment for Base Price of $127.5 Million
Newpark Resources Sells Fluids Systems Segment for Base Price of $127.5 Million
Sep 13, 2024
04:56 PM EDT, 09/13/2024 (MT Newswires) -- Newpark Resources ( NR ) said late Friday it has completed the sale of its Fluids Systems segment to SCF Partners for a base price of $127.5 million. The company said it expects to recognize a loss on the transaction. As a result, Newpark is estimated to generate additional US federal net operating...
Copyright 2023-2026 - www.financetom.com All Rights Reserved